VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed a share buyback on 22 May 2026, acquiring 9,000 ordinary shares on the Hong Kong Stock Exchange and transferring them to treasury stock.

• Transaction details – Repurchase date: 22 May 2026 – Volume: 9,000 shares, representing 0.008 % of the company’s issued share capital (excluding treasury shares) prior to the transaction – Price range: HKD 23.48–24.00 per share – Volume-weighted average price: HKD 23.82 – Total consideration: HKD 0.21 million

• Share-capital impact – Issued shares (excluding treasury shares) decreased to 113.89 million from 113.90 million – Treasury shares increased to 33,200 from 24,200 – Total issued shares remained unchanged at 113.93 million

• Repurchase mandate utilisation – Shareholders approved a mandate on 27 June 2025 authorising the repurchase of up to 11.39 million shares. – Cumulative repurchases under the mandate now stand at 33,200 shares, equal to 0.03 % of the company’s issued shares on the mandate date.

• Post-repurchase restrictions – In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 21 June 2026.